There is a near-term focus on partnerships, collaborations and licensing deals to maximise the revenue potential of Oxford BioDynamics’ portfolio of innovative and clinically robust tests. We believe the market opportunities for CiRT, PSE, and the portfolio of tests remain intact and sizeable, but successful uptake requires continued significant commercial investment and/or partners, in our view. New management is considering all options to crystallise value from these diagnostic tests and the in-depth knowledge of 3-dimensional genomics that underpin the proprietary EpiSwitch platform. Our reinstated DCF-based valuation is now £159m ($199m), or 8p/share, which assumes OBD can deliver on the revenue and value potential that exists.
